Medline Inc.
MDLN Healthcare Medical Instruments & Supplies
Medline Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.4 billion, up 11.5% from fiscal 2024.
- Revenue
- +14.1%
- Free cash flow
- +916.1%
- Total debt
- −23.7%
Quarter to September 2026, against a year earlier
Follow MDLN
Alert me
Medline Inc. (MDLN) Free cash flow
Medline Inc.'s free cash flow for fiscal 2025 was $1.3B, down 8.34% from $1.4B in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.1B. Medline Inc. ranks 3rd of 51 Medical Instruments & Supplies companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $1.3B | (8.34%) |
| FY2024 | $1.4B | 0.35% |
| FY2023 | $1.4B | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | $884.0M | 46.36% |
| Jun 2026 | $604.0M | 91.14% |
| Mar 2026 | $316.0M | (75.64%) |
| Dec 2025 | $1.3B | 1,390.80% |
| 4 more quarters | Free account |
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| ISRG Intuitive Surgical, Inc. compare | $3.6B |
| BDX Becton, Dickinson and Company compare | $3.2B |
| MDLN Medline Inc. | $3.1B |
| ALC Alcon compare | $1.6B |
| RMD ResMed Inc. compare | $1.6B |
| BAX Baxter International Inc. compare | $1.1B |
| COO The Cooper Companies, Inc. compare | $678.0M |
| WST West Pharmaceutical Services, Inc. compare | $453.4M |
| SOLV Solventum Corporation compare | $0.00 |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on MDLN
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Book value per share
- The full statement